BIOMAT Database Logo BIOMAT Database Logo

Immunolocalization of transitional cell carcinoma of the bladder with intravesically administered technetium-99m labelled HMFG1 monoclonal antibody. 1995

J Malamitsi, and J Zorzos, and A D Varvarigou, and S Archimandritis, and C Dassiou, and D V Skarlos, and P Dimitriou, and M Likourinas, and A Zizi, and C Proukakis
Department of Nuclear Medicine, Hippocrateion Hospital, Athens, Greece.

The aim of this study was the immunolocalization of transitional cell carcinoma of the bladder with a radiolabelled murine tumour-associated monoclonal antibody and the measurement of the absolute uptake of the antibody by the tumour. Fourteen patients with transitional cell carcinoma of the bladder received 3-6 mCi (111-222 MBq) of technetium-99m labelled HMFG1 monoclonal antibody intravesically and one patient, 2 mCi (74 MBq) of iodine-131 labelled 11.4.1, which is a non-tumour-specific monoclonal antibody. Four of the 15 patients were evaluated with single-photon emission tomography (SPET) 1 1/2 to 2 h post administration. All patients underwent transurethral resection of the bladder tumour within 12-20 h following intravesical administration of the radiolabelled antibody. The radioactivity of biopsy specimens from normal urothelium and tumour areas were counted in a gamma counter. The mean uptake of the radiolabelled antibodies from normal and tumour sites was expressed as a percentage of the administered dose per kilogram of tissue. Conventional histology and immunohistochemistry using HMFG1 monoclonal antibody were performed on paraffin sections of the biopsy specimens. Although our results are preliminary, it can be concluded that: (a) bladder tumours are well imaged by SPET when using 99mTc-HMFG1; (b) intravesically administered radiolabelled antibody remains on the bladder tissue and does not escape into the systemic circulation; (c) the wide range of tumour uptake values (0%-9.3% administered dose/kg) observed probably can be attributed to heterogeneity of the antigenic expression of the tumour; (d) values of 99mTc-HMFG1 monoclonal antibody uptake by the tumour do not justify future attempts at radioimmunotherapy.

UI MeSH Term Description Entries
D007457 Iodine Radioisotopes Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes. Radioisotopes, Iodine
D001749 Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER. Bladder Cancer,Bladder Neoplasms,Cancer of Bladder,Bladder Tumors,Cancer of the Bladder,Malignant Tumor of Urinary Bladder,Neoplasms, Bladder,Urinary Bladder Cancer,Bladder Cancers,Bladder Neoplasm,Bladder Tumor,Cancer, Bladder,Cancer, Urinary Bladder,Neoplasm, Bladder,Neoplasm, Urinary Bladder,Tumor, Bladder,Tumors, Bladder,Urinary Bladder Neoplasm
D002295 Carcinoma, Transitional Cell A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS. Carcinomas, Transitional Cell,Cell Carcinoma, Transitional,Cell Carcinomas, Transitional,Transitional Cell Carcinoma,Transitional Cell Carcinomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000283 Administration, Intravesical The instillation or other administration of drugs into the bladder, usually to treat local disease, including neoplasms. Bladder Drug Administration,Drug Administration, Bladder,Instillation, Bladder,Intravesical Drug Administration,Administration, Intravesical Drug,Injections, Intravesical,Intravesical Administration,Intravesical Injection,Intravesical Instillation,Administration, Bladder Drug,Administrations, Bladder Drug,Administrations, Intravesical,Administrations, Intravesical Drug,Bladder Drug Administrations,Bladder Instillation,Bladder Instillations,Drug Administration, Intravesical,Drug Administrations, Bladder,Drug Administrations, Intravesical,Injection, Intravesical,Instillation, Intravesical,Instillations, Bladder,Instillations, Intravesical,Intravesical Administrations,Intravesical Drug Administrations,Intravesical Injections,Intravesical Instillations
D013667 Technetium The first artificially produced element and a radioactive fission product of URANIUM. Technetium has the atomic symbol Tc, and atomic number 43. All technetium isotopes are radioactive. Technetium 99m (m Technetium 99m,99m, Technetium
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D015899 Tomography, Emission-Computed, Single-Photon A method of computed tomography that uses radionuclides which emit a single photon of a given energy. The camera is rotated 180 or 360 degrees around the patient to capture images at multiple positions along the arc. The computer is then used to reconstruct the transaxial, sagittal, and coronal images from the 3-dimensional distribution of radionuclides in the organ. The advantages of SPECT are that it can be used to observe biochemical and physiological processes as well as size and volume of the organ. The disadvantage is that, unlike positron-emission tomography where the positron-electron annihilation results in the emission of 2 photons at 180 degrees from each other, SPECT requires physical collimation to line up the photons, which results in the loss of many available photons and hence degrades the image. CAT Scan, Single-Photon Emission,CT Scan, Single-Photon Emission,Radionuclide Tomography, Single-Photon Emission-Computed,SPECT,Single-Photon Emission-Computed Tomography,Tomography, Single-Photon, Emission-Computed,Single-Photon Emission CT Scan,Single-Photon Emission Computer-Assisted Tomography,Single-Photon Emission Computerized Tomography,CAT Scan, Single Photon Emission,CT Scan, Single Photon Emission,Emission-Computed Tomography, Single-Photon,Radionuclide Tomography, Single Photon Emission Computed,Single Photon Emission CT Scan,Single Photon Emission Computed Tomography,Single Photon Emission Computer Assisted Tomography,Single Photon Emission Computerized Tomography,Tomography, Single-Photon Emission-Computed
D016719 Radioimmunodetection Use of radiolabeled antibodies for diagnostic imaging of neoplasms. Antitumor antibodies are labeled with diverse radionuclides including iodine-131, iodine-123, indium-111, or technetium-99m and injected into the patient. Images are obtained by a scintillation camera. Immunoscintigraphy, Radiolabeled,Radioimmunoimaging,Radioimmunoscintigraphy,Immunoscintigraphy, Radiolabelled,Radiolabeled Immunoscintigraphy,Radiolabelled Immunoscintigraphy,Immunoscintigraphies, Radiolabeled,Immunoscintigraphies, Radiolabelled,Radioimmunodetections,Radioimmunoimagings,Radioimmunoscintigraphies,Radiolabeled Immunoscintigraphies,Radiolabelled Immunoscintigraphies

Related Publications

J Malamitsi, and J Zorzos, and A D Varvarigou, and S Archimandritis, and C Dassiou, and D V Skarlos, and P Dimitriou, and M Likourinas, and A Zizi, and C Proukakis
[Radioimmunoimaging of bladder tumor with the intravesical administration of technetium -99m labelled monoclonal antibody].
January 1998, Zhonghua wai ke za zhi [Chinese journal of surgery],
J Malamitsi, and J Zorzos, and A D Varvarigou, and S Archimandritis, and C Dassiou, and D V Skarlos, and P Dimitriou, and M Likourinas, and A Zizi, and C Proukakis
Whole bladder wall photodynamic therapy of transitional cell carcinoma rat bladder tumors using intravesically administered hypericin.
November 2003, International journal of cancer,
J Malamitsi, and J Zorzos, and A D Varvarigou, and S Archimandritis, and C Dassiou, and D V Skarlos, and P Dimitriou, and M Likourinas, and A Zizi, and C Proukakis
Radioimmunoscintigraphy with technetium-99m labelled monoclonal antibody, 1A3, in colorectal cancer.
August 1993, European journal of nuclear medicine,
J Malamitsi, and J Zorzos, and A D Varvarigou, and S Archimandritis, and C Dassiou, and D V Skarlos, and P Dimitriou, and M Likourinas, and A Zizi, and C Proukakis
Radioimmunoscintigraphy with technetium-99m labelled monoclonal antibody, 1A3, in colorectal cancer.
November 1993, European journal of nuclear medicine,
J Malamitsi, and J Zorzos, and A D Varvarigou, and S Archimandritis, and C Dassiou, and D V Skarlos, and P Dimitriou, and M Likourinas, and A Zizi, and C Proukakis
Radioimmunoscintigraphy with technetium-99m-labelled monoclonal antibody, SM3, in gynaecological cancer.
June 1993, European journal of nuclear medicine,
J Malamitsi, and J Zorzos, and A D Varvarigou, and S Archimandritis, and C Dassiou, and D V Skarlos, and P Dimitriou, and M Likourinas, and A Zizi, and C Proukakis
Immunoscintigraphy with iodine-131-labelled monoclonal antibody AUA1 in patients with transitional cell carcinoma of the bladder.
January 1994, Urological research,
J Malamitsi, and J Zorzos, and A D Varvarigou, and S Archimandritis, and C Dassiou, and D V Skarlos, and P Dimitriou, and M Likourinas, and A Zizi, and C Proukakis
Radioimmunoscintigraphy of ovarian tumours with technetium-99m labelled monoclonal antibody-170: first clinical experiences.
July 1995, European journal of nuclear medicine,
J Malamitsi, and J Zorzos, and A D Varvarigou, and S Archimandritis, and C Dassiou, and D V Skarlos, and P Dimitriou, and M Likourinas, and A Zizi, and C Proukakis
[Labeling of antihuman bladder carcinoma monoclonal antibody with a technetium-99m and radioimmunoimaging of human bladder carcinoma xenograft in nude mice].
January 1996, Zhonghua wai ke za zhi [Chinese journal of surgery],
J Malamitsi, and J Zorzos, and A D Varvarigou, and S Archimandritis, and C Dassiou, and D V Skarlos, and P Dimitriou, and M Likourinas, and A Zizi, and C Proukakis
Chronic complicated osteomyelitis of the appendicular skeleton: diagnosis with technetium-99m labelled monoclonal antigranulocyte antibody-immunoscintigraphy.
July 1997, European journal of nuclear medicine,
J Malamitsi, and J Zorzos, and A D Varvarigou, and S Archimandritis, and C Dassiou, and D V Skarlos, and P Dimitriou, and M Likourinas, and A Zizi, and C Proukakis
A novel anti-seminoma monoclonal antibody (M2A) labelled with technetium-99m: potential application for radioimmunoscintigraphy.
February 1995, British journal of urology,
Copied contents to your clipboard!